For US Healthcare Professionals

You are now leaving the site

Are you sure you want to leave?

Identifying Appropriate Patients

Targeted care can change the treatment outcome for patients with Thyroid Eye Disease (TED).

Identify your appropriate patients for Thyroid Eye Disease treatment.
Confirm confidently. Intervene promptly.

After TED is diagnosed, use this 1+1 checklist to determine when signs/symptoms and triggers call for treatment.

Graphic indicating when there is one core sign or symptom plus one present trigger it is time to treat thyroid eye disease (TED) Graphic indicating when there is one core sign or symptom plus one present trigger it is time to treat thyroid eye disease (TED)

Core sign or symptom

Proptosis1,2

  • Eye bulging in one or both eyes

  • Protruding eyeballs

  • Inability to close eyes

 Diplopia2

  • Double vision

  • May close one eye while reading or driving

  • Eyes don’t move together/vertically misaligned

 Orbital Pain1,2

  • Persistent ache around the eye socket or brow area

  • Pain or pressure behind the eyes

  • Pain that worsens with eye movement

Present trigger

Impact to Activities of Daily Living (ADLs)3

  • Difficulty reading or driving

  • Impact on self-confidence

  • Social withdrawal or appearance concerns

  • Impact on work, hobbies, or relationships

 Inflammation1

  • Redness, swelling, or irritation

  • Patient reports eyes feel “puffy” or “inflamed”

  • Swelling of caruncle or plica

  • Swelling of conjunctiva

 Worsening Over Time1,4

  • New or progressing symptoms

  • Change in pain level

  • Change in proptosis, diplopia, or orbital pain

  • Changes observed in recent photos
divider-line divider-line-mb

After TED is diagnosed, determine when signs/symptoms and triggers call for treatment.

Don’t wait for TED to progress. After all, TED doesn’t follow just one path—some patients progress slowly while others flare unpredictably. When you see at least 1 sign of TED + 1 trigger, act to help moderate to severe patients like these.

Jas, a TEPEZZA® patient before TEPEZZA® treatment Jas, a TEPEZZA® patient before TEPEZZA® treatment

Clinical History

  • Age: 45 years old

  • Endocrine-related conditions: Graves’ disease, postprocedural hypothyroidism, type 2 diabetes

  • Time since TED diagnosis: ~4 years

  • Treatment history: Radioactive iodine, orbital decompression surgery, levothyroxine, diabetes medication

Signs & Symptoms

  • Proptosis

  • Dryness

  • Eye pain

Present Triggers

  • Decreased participation in activities

  • Worsening eye symptoms, including inflammation

Jas, real TEPEZZA patient (compensated for her time)

Jas’s symptoms progressed as she waited for a specialist to intervene

jas-primary-care-physician jas-primary-care-physician
Primary Care Physician

Managed hypothyroidism post-radioactive iodine treatment. Noted persistent eye symptoms and referred to an endocrinologist

jas-endocrinologist jas-endocrinologist
Endocrinologist

Confirmed history of Graves’ disease and hypothyroidism. Diagnosed TED and initiated TEPEZZA after symptoms worsened

Jas’s endocrinologist made a difference in her treatment journey by recognizing TED and initiating TEPEZZA.
Lily, a TEPEZZA® patient before TEPEZZA® treatment Lily, a TEPEZZA® patient before TEPEZZA® treatment

Clinical History

  • Age/Gender: 24-year-old female

  • Endocrine-related conditions: Graves’ disease, hyperthyroidism

  • Time since TED diagnosis: 1 year

  • Treatment history: Eye drops, compresses

Signs & Symptoms

  • Proptosis (22 mm OU)

  • Orbital pain

  • Dryness and itchiness

Present Triggers

  • Decreased participation in hobbies

  • Inflammation

  • Recent worsening of eye symptoms

OU, oculus uterque (both eyes).

“The symptoms didn’t feel mild to me. My eyes would get really swollen. I’d have to ice them instead of going out, being active, and doing things I enjoy.”
– Lily, real TEPEZZA patient (compensated for her time)

Lily’s symptoms progressed as she waited for a specialist to intervene

lily-primary-care-physician lily-primary-care-physician
Primary Care Physician

Suspected hyperthyroidism and referred to endocrinologist

lily-endocrinologist lily-endocrinologist
Endocrinologist

Diagnosed Lily with Graves’ disease, hyperthyroidism, and TED; referred for care

lily-endocrinologist lily-endocrinologist
lily-endocrinologist lily-endocrinologist
Oculoplastic Surgeon

Introduced Lily to TEPEZZA

Lily had to find the right specialist to diagnose her Thyroid Eye Disease (TED) and then was referred to another specialist who prescribed treatment.

  • Patients with TED face an average 5-year diagnostic journey, which can lead to delayed care and continued impact on your patients’ daily lives5. To ensure your patients are on the right care pathway, locate a TED Specialist.

  • Locate a TED Specialist

Paris, a TEPEZZA® patient before TEPEZZA® treatment Paris, a TEPEZZA® patient before TEPEZZA® treatment

Clinical History

  • Age/Gender: 38-year-old female

  • Endocrine-related conditions: Graves’ disease

  • Time since TED diagnosis: 4 years

  • Treatment history: Steroids

Signs & Symptoms

  • Proptosis

  • Constant diplopia

  • Orbital pain

Present Triggers

  • Impact on activities of daily living (driving at night; difficulty reading)

  • Inflammation

  • Worsening of eye symptoms over time

“I would experience a lot of double vision, and that became more pronounced as the bulging become more pronounced as well.”
– Paris, real TEPEZZA patient (compensated for her time)

Paris’s symptoms progressed as she waited for a specialist to intervene

paris-primary-care-physician paris-primary-care-physician
Primary Care Physician

Diagnosed with Graves’ disease; referred to an endocrinologist

paris-endocrinologist paris-endocrinologist
Endocrinologist

Treated symptoms of Graves’ disease; referred to an optometrist after eye symptoms emerged

paris-oculoplastic paris-oculoplastic
Optometrist

Suspected a thyroid-related eye condition; sent to an ophthalmologist as symptoms progressed

paris-several-months-later paris-several-months-later
paris-ophthalmologist paris-ophthalmologist
Ophthalmologist

Confirmed diagnosis of TED and introduced Paris to TEPEZZA

Diagnosis of TED can take 2-5 years.5 A visit to your office can help lay a new treatment path for your patients.
Real patient results

Real patient results

bar-icon

See TEPEZZA clinical improvements across key Thyroid Eye Disease (TED) signs and symptoms

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of inflammatory bowel disease (IBD). IBD has been reported in some patients without a prior diagnosis of IBD. Monitor patients for signs and symptoms of IBD. If IBD exacerbation is suspected, discontinue use of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.

Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients’ hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, ear discomfort, weight decreased, nail disorders, and menstrual disorders.

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

Please see Full Prescribing Information for more information.
REFERENCES:

1. Barrio-Barrio J, Sabater AL, Bonet-Farriol E, et al. Graves’ ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol. 2015;2015:249125. 2. Bothun ED, Scheurer RA, Harrison AR, Lee MS. Update on thyroid eye disease and management. Clin Ophthalmol. 2009;3:543-551. 3. Smith TJ, Cockerham K, Conrad E, Holt RJ. (2023, May 4-6). Assessment of the thyroid eye disease specific Graves’ ophthalmopathy quality of life questionnaire in noninflammatory or inactive thyroid eye disease patients. American Association of Clinical Endocrinology meeting. Seattle, WA. 4. National Organization for Rare Diseases. Thyroid Eye Disease. Rarediseases.org/rare-diseases/thyroid-eye-disease. Accessed February 15, 2026. 5. Data on File. Amgen. April 2020.